Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder

Female Sexual Dysfunction Clinical Trial

Official title:

Phase 2 Clinical Study to Evaluate the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Gel Form Applied to Women With Sexual Arousal Disorder

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06116045
• Other study ID #: BZ371CLI601
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 1, 2024
• Est. completion date: August 1, 2024

Study information

• Verified date: October 2023
• Source: Biozeus Biopharmaceutical S.A.
• Contact: Camilla Trindade, PhD
• Phone: +55 21 25239089
• Email: camilla.nunes[@]biozeus.com.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder.

Description:

FSAD is defined as the recurrent inability to attain or maintain sufficient genital arousal during sexual activity. Therefore, a healthy blood flow is central to the physiological processes related to sexual arousal, leading to genital lubrication, warmth, and clitoral protrusion. The vasculature and blood flow in vaginal tissue can be compromised due to natural aging and various risk factors, including cigarette smoking, alcohol abuse, lack of exercise, high-fat diets, hypertension, hypercholesterolemia, and diabetes mellitus. All these risk factors and conditions are highly prevalent among women and can lead to FSAD. BZ371A offers a potential solution by increasing blood flow in genital tissue through its unique mechanism of action, thereby restoring vascular homeostasis and the physiological processes related to sexual arousal in women.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: August 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years to 60 Years

Eligibility

Inclusion Criteria:

• Women between the ages 21 and 60;
• Pre-menopausal or post-menopausal women may be included;
• May or may not be taking female sex hormones (estrogen with or without progesterone, or their derivatives);
• FSAD, defined as the inability, persistent or recurrent, to obtain or maintain until the conclusion of sexual activity an adequate genital response to sexual arousal (lubrication, warmth and enlargement of the clitoris);
• Women with FSAD who present marked suffering or interpersonal difficulties;
• Stable relationship for more than 6 months, with a sexually active partner;
• Ability to read and understand the Informed Consent Form (ICF) and to answer the questionnaires.

Exclusion Criteria:

• Women who do not agree to use a contraceptive method and who have the capacity to become pregnant during the study;
• Women who do not agree to attempt sexual activity at least twice a week while taking the study medication;
• History of unresolved sexual trauma or abuse;
• Diagnosis of vaginismus, genitopelvic pain/penetration disorder and/or sexual aversion disorder;
• Uncontrolled diabetes at screening visit (HbA1C > 10%);
• Prior spinal cord injury, with lower limb paralysis;
• History of abdominal or pelvic surgery that may have damaged pelvic nerves, including vulvectomy, colostomy, cytostomy, hysterectomy, or bladder suspension.
• Current testosterone use, or long-term testosterone use (such as chip) within the past 6 months;
• Presence of menstrual irregularity or endocrinopathies that alter the menstrual cycle;
• Patients with current depression, characterized by the use or need for use of psychotropic drugs, including bupropion, lithium, or neuroleptics;
• Presence of genital lesions that impair analysis of local adverse effects on the genitalia;
• Presence of diseases that cause excessive vaginal discharge, such as recurrent urinary tract infection, vaginal infection and pelvic inflammatory disease.
• Abnormal Papanicolaou test within the past 3 years;
• History of gynecological cancer (history of uterine dysplasia can be included, provided it has been properly treated for at least 6 months);
• History of pelvic irradiation;
• Use of topical medications in the genital region that may interfere with PSI assessment as well as their absorption or drug interaction, including vaginal estrogens, lubricants, spermicides, creams or gels, vaginal douches;
• History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart disease (including history of angina and/or heart failure) and nephropathies;
• Current use of nitrates, such as propatylnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and isosorbitol dinitrate (Isocord®)
• ECG findings that are clinically symptomatic, or that, in the Investigator's judgment, are considered significant and pose a risk to the research volunteer's participation;
• Findings on laboratory tests that, in the Investigator's judgment, are considered significant and offer risk to the research volunteer's participation or may hinder the study analyses;
• TSH outside normal limits for age (participants with hypothyroidism on stable dose of medication, over 3 months, may be included);
• BP outside safe limits: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except for situations such as "white coat" syndrome
• Severe hypertension, considered as use of three or more antihypertensives;
• Diseases that can cause clitoral priapism, such as sickle cell anemia, multiple myeloma or leukemia;
• History of clitoral priapism;
• Current relevant diarrhea, defined as duration over four weeks, association with abdominal pain or malabsorptive syndrome, or presence of mucus, pus, or blood in the stool;
• Pregnant or lactating;
• Current use of nitric oxide donors, guanylate cyclase stimulators (e.g. Riociguat), or 5- phosphodiesterase inhibitors (Sildenafil, Tadalafil, etc.);
• Any disease or condition or physical finding that the Investigator considers significant and that increases the risk of the research participant's participation or may interfere with the results, including serious debilitating diseases, presence of cancer, serious mental illness, persistent abuse of medication.

Related Conditions & MeSH terms

• Female Sexual Arousal Disorder
• Female Sexual Dysfunction
• Sexual Dysfunctions, Psychological

Intervention

Drug:
• BZ371A 7.5 mg (1.5 ml)
7.5 mg gel
• BZ371A 5.0 mg (1.0 ml)
5.0 mg gel
• BZ371A 2.5 mg (0.5 ml)
2.5 mg gel
• Placebo (1.5 ml)
BZ371A-matched placebo
• Placebo (1.0 ml)
BZ371A-matched placebo
• Placebo (0.5 ml)
BZ371A-matched placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Biozeus Biopharmaceutical S.A.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy in increasing arousal	Evaluation of the efficacy of BZ371A in increasing arousal using Female Sexual Encounter Profile (FSEP) questionnaire. The study will evaluate number of "yes" answers to question 3 in the Female Sexual Encounter Profile (FSEP) questionnaire, divided by the number of valid attempts (question 7 of the FSEP).; The study will evaluate the increase in the FSEP score based on the baseline FSEP value, obtained before using the BZ371A. Thus, the higher the number of yes answers, the better the efficacy of the drug.	Baseline, 4 weeks and 8 weeks
Secondary	Efficacy in increasing desire, lubrification, orgasm and arousal	Evaluation of the success rate for desire, lubrification, orgasm and for arousal using Female Sexual Encounter Profile (FSEP). The number of successes for desire will be assessed using FSEP Question 2 / FSEP Question 7, for lubrication FSEP Question 4 / FSEP Question 7, for orgasm FSEP Question 5 / FSEP Question 7 and for the degree of arousal FSEP Question 6 / FSEP Question 7.; For each question, the number of "yes" answers will be counted as success. Therefore, for each "no" answer the value will be 0 and for each "yes" answer the value will be 1.	Baseline, 4 weeks and 8 weeks
Secondary	Evaluation of the quality of female sexual encounters	Evaluation based on the total score of the Female Sexual Encounter Profile (FSEP) questionnaire. The score ranges from 0 to 9. Therefore, the higher the score, the better the participant's sexual encounter.	Baseline, 4 weeks and 8 weeks
Secondary	Efficacy in increasing genital blood flow	Evaluation of the efficacy of BZ371A in increasing genital blood flow using Cytocam system	Baseline, 4 weeks (pre-dose, 15, 30, 60, 90, 120 and 240 minutes) and 8 weeks (pre-dose, 15, 30, 60, 90, 120 and 240 minutes)
Secondary	Female Sexual Function Index (FSFI)	Evaluation of the score for each domain (Desire, Arousal, Lubrication, Orgasm, Satisfaction, Pain) using the Female Sexual Function Index (FSFI) questionnaire. The score ranges from 2 to 36. Thus, the higher the score, the better the participant's sexual satisfaction.	Baseline, 4 weeks and 8 weeks
Secondary	Assessment of treatment satisfaction	Response rate to the Global Assessment Question (GAQ), by the number of "yes" answers to the question about arousal and sexual pleasure.	4 weeks after baseline and 8 weeks after baseline
Secondary	Adverse effects report	Adverse effects evaluation of compound use and application	4 weeks after baseline, 8 weeks after baseline and, approximately, 11 weeks after baseline
Secondary	Physical examination of the genitalia	Number of participants with abnormal physical exam findings in the applied region.	From up to 30 days before Baseline, Baseline, 4 weeks, 8 weeks and, approximately, 11 weeks
Secondary	Change in systemic blood pressure	Change in Diastolic Blood Pressure and Systolic Blood Pressure	From up to 30 days before Baseline, Baseline, 4 weeks, 8 weeks and, approximately, 11 weeks
Secondary	Change in Heart Rate (HR)	Change in Heart Rate	From up to 30 days before Baseline, Baseline, 4 weeks, 8 weeks and, approximately, 11 weeks
Secondary	Basal chest electrocardiogram (ECG)	Number of participants with abnormal electrocardiogram (ECG) findings.	From up to 30 days before Baseline, 4 weeks after baseline, 8 weeks after baseline and, approximately, 11 weeks after baseline
Secondary	Blood evaluation	Number of participants with abnormal laboratory test results	From up to 30 days before Baseline, 4 weeks after baseline and 8 weeks after baseline
Secondary	Urine evaluation	Number of participants with abnormal laboratory test results	From up to 30 days before Baseline, 4 weeks after baseline and 8 weeks after baseline